Yahoo · Aug 14, 2026
Lineage Cell Therapeutics (LCTX) Q2 2026 Earnings Call Transcript
CEO outlines manufacturing scale-up strategy for cell therapies amid $50.8M cash runway.
LC
AMEX · LCTX
Lineage Cell Therapeutics, Inc.
Healthcare · Biotechnology
$1.11
Down-$0.05 (-4.31%)
Updated Aug 29, 2026, 1:48 PM
SID Score
3.6/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 396.81M
- P/E ratio
- -5.83
- Dividend yield
- 0.00%
- 52-week range
- $1.00 – $1.86
- Volume
- 587.28K
- Avg. volume
- 1.99M
Price performance
LCTX price history
1M range · 21 trading sessions · Daily adjusted prices
LCTX closed at $1.11 after 21 trading sessions, up 2.78% for the selected period.
- Last close
- $1.11
- Period change
- +2.78%
- Period low
- $1.06
- Period high
- $1.16
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 28, 2026 | $1.16 | $1.1762 | $1.11 | $1.11 | 587.28K |
| Aug 27, 2026 | $1.11 | $1.185 | $1.102 | $1.16 | 970.06K |
| Aug 26, 2026 | $1.16 | $1.16 | $1.095 | $1.12 | 807.69K |
| Aug 25, 2026 | $1.08 | $1.13 | $1.08 | $1.13 | 1.03M |
| Aug 24, 2026 | $1.08 | $1.11 | $1.06 | $1.09 | 607.68K |
| Aug 21, 2026 | $1.09 | $1.1081 | $1.07 | $1.08 | 716.42K |
| Aug 20, 2026 | $1.09 | $1.0991 | $1.04 | $1.08 | 1.47M |
| Aug 19, 2026 | $1.09 | $1.13 | $1.079 | $1.10 | 951.49K |
| Aug 18, 2026 | $1.06 | $1.08 | $1.045 | $1.06 | 1.11M |
| Aug 17, 2026 | $1.07 | $1.1072 | $1.06 | $1.06 | 795.39K |
| Aug 14, 2026 | $1.06 | $1.09 | $1.05 | $1.07 | 1.13M |
| Aug 13, 2026 | $1.11 | $1.118 | $1.05 | $1.06 | 957.59K |
| Aug 12, 2026 | $1.12 | $1.1291 | $1.09 | $1.10 | 698.01K |
| Aug 11, 2026 | $1.13 | $1.1478 | $1.095 | $1.12 | 763.81K |
| Aug 10, 2026 | $1.10 | $1.15 | $1.09 | $1.13 | 752.41K |
| Aug 7, 2026 | $1.10 | $1.14 | $1.08 | $1.10 | 833.65K |
| Aug 6, 2026 | $1.16 | $1.18 | $1.12 | $1.13 | 711.64K |
| Aug 5, 2026 | $1.12 | $1.15 | $1.10 | $1.14 | 693.09K |
| Aug 4, 2026 | $1.13 | $1.15 | $1.11 | $1.12 | 860.81K |
| Aug 3, 2026 | $1.08 | $1.12 | $1.0711 | $1.11 | 680.72K |
| Jul 31, 2026 | $1.11 | $1.13 | $1.07 | $1.08 | 948.85K |
Latest LCTX news
The latest Smart Investors Daily articles mentioning LCTX.
Stock researchCompany · Overview
LCTX research
Overview
Company profile and research snapshot.
Company profile
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 14, 2026 | HC Wainwright & Co. | Buy | — |
| May 4, 2026 | D. Boral Capital | Buy | — |
| Apr 28, 2026 | Canaccord Genuity | Buy | — |
| Mar 25, 2026 | B. Riley Securities | Buy | — |
| Mar 24, 2026 | HC Wainwright & Co. | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Aug 9, 2026
Lineage Cell Therapeutics Q2 Earnings Call Highlights
Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) outlined progress across its cell-therapy pipeline during its second-quarter 2026 earnings call, highlighting preclinical advances in corneal disease, Type 1 diabetes and hearing loss programs while Roche and Genentech continue surgical-delivery optimiza
Yahoo · Aug 7, 2026
Lineage Cell Therapeutics, Inc. Q2 2026 Earnings Call Summary
Moby summary of Lineage Cell Therapeutics, Inc.'s Q2 2026 earnings call
Yahoo · Aug 7, 2026
Lineage Cell Therapeutics Inc (LCTX) (Q2 2026) Earnings Call Highlights: Cash Runway Extended, ...
Lineage Cell Therapeutics Inc (LCTX) reports net income of $1.5 million, extends cash runway into Q3 2028, and advances key pipeline programs despite revenue decline.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
